Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838252 | 0.85 | MAPT (0.60) | ALDH1A1TAS2R38CA2CA1KMT2A | |
| SCHEMBL1110923 | 0.83 | ALDH1A1 (0.63) | ALDH1A1TAS2R38CA2CA1KMT2A | |
| 4-Chloro-Benzoic Acid SCHEMBL9317543 | 0.83 | TAS2R38 (0.59) | ALDH1A1TAS2R38KMT2AMEN1RAB9A | |
| 4-Chloro-Benzoic Acid SCHEMBL9316888 | 0.83 | TAS2R38 (0.59) | ALDH1A1TAS2R38KMT2AMEN1RAB9A | |
| Acedoben SCHEMBL24320 | 0.83 | ALDH1A1 (0.68) | ALDH1A1EPHX2NR1H4CA2CA1 | |
| SCHEMBL14511451 | 0.82 | TAS2R38 (0.75) | ALDH1A1TAS2R38NR1H4CA2CA1 | |
| Acedoben SCHEMBL11793874 | 0.81 | ALDH1A1 (0.66) | ALDH1A1EPHX2NR1H4CA2CA1 | |
| Acedoben SCHEMBL3464430 | 0.81 | ALDH1A1 (0.66) | ALDH1A1EPHX2NR1H4CA2CA1 | |
| Acedoben SCHEMBL1458995 | 0.81 | ALDH1A1 (0.66) | ALDH1A1EPHX2NR1H4CA2CA1 | |
| Acedoben SCHEMBL11274912 | 0.81 | ALDH1A1 (0.66) | ALDH1A1EPHX2NR1H4CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | claimed |
| EP-3320921-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3320921-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Ala Wai Pharma, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2217216-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9579383-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8609139-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | UNIVERSITY OF HAWAII | 2011-08-25 | — | — | US | disclosed |
| EP-2217216-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Scolr Pharma, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | disclosed |
| WO-2009061805-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SCOLR PHARMA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | ALDH1A1 3807/4885TAS2R38 1066/4885EPHX2 1213/4885 |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | ALDH1A1 3807/4885TAS2R38 1066/4885EPHX2 1213/4885 |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | ALDH1A1 3807/4885TAS2R38 1066/4885EPHX2 1213/4885 |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | ALDH1A1 3807/4885TAS2R38 1066/4885EPHX2 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.